Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Early Access Program for Voxelotor for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older in Europe and other regions outside the United States

Next Previous
X
Search
Trial Profile

An Early Access Program for Voxelotor for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older in Europe and other regions outside the United States

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Dec 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Sickle cell anaemia
  • Focus Expanded access; Therapeutic Use
  • Sponsors Global Blood Therapeutics

    • Most Recent Events

    • 11 Dec 2020 New trial record
    • 02 Dec 2020 According to a GBT media release, the company announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top